Leerink Partnrs Predicts AbbVie's Q3 Earnings (NYSE:ABBV)

Key Points

• Leerink Partners has upgraded its Q3 2025 earnings per share (EPS) estimate for AbbVie to $3.34, indicating a positive outlook for the company's financial performance.
• AbbVie reported $2.97 EPS for its last quarter, missing expectations, but achieved revenue of $15.42 billion, exceeding projections.
• The company recently declared a quarterly dividend of $1.64, contributing to an annualized dividend yield of 3.4% and a high dividend payout ratio of 312.38%.

AbbVie Inc. (NYSE:ABBV - Free Report) - Equities researchers at Leerink Partnrs lifted their Q3 2025 earnings estimates for AbbVie in a note issued to investors on Thursday, July 31st. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn $3.34 per share for the quarter, up from their previous estimate of $3.18. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie's Q4 2025 earnings at $3.27 EPS, FY2026 earnings at $14.27 EPS, FY2027 earnings at $16.01 EPS, FY2028 earnings at $18.15 EPS and FY2029 earnings at $19.59 EPS.

ABBV has been the topic of several other research reports. Citigroup raised their price target on shares of AbbVie to $205.00 and gave the stock a "hold" rating in a research note on Wednesday, June 11th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $194.00 price target on shares of AbbVie in a research note on Tuesday, April 8th. Morgan Stanley raised their price target on shares of AbbVie from $250.00 to $255.00 and gave the stock an "overweight" rating in a research note on Friday. Evercore ISI raised their price target on shares of AbbVie from $204.00 to $205.00 and gave the stock an "outperform" rating in a research note on Monday, April 28th. Finally, Cantor Fitzgerald initiated coverage on shares of AbbVie in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 target price on the stock. Eight research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and an average target price of $212.81.

AbbVie Trading Up 0.9%

ABBV stock traded up $1.83 during trading on Monday, hitting $197.05. The company had a trading volume of 4,216,467 shares, compared to its average volume of 5,844,660. The firm has a market capitalization of $348.07 billion, a P/E ratio of 93.83, a PEG ratio of 1.27 and a beta of 0.50. AbbVie has a 52-week low of $163.81 and a 52-week high of $218.66. The company has a 50 day simple moving average of $188.33 and a 200-day simple moving average of $190.42. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing the consensus estimate of $3.24 by ($0.27). The company had revenue of $15.42 billion during the quarter, compared to analysts' expectations of $14.93 billion. AbbVie had a return on equity of 518.10% and a net margin of 6.45%. The company's quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the business earned $2.65 EPS.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.3%. The ex-dividend date is Tuesday, July 15th. AbbVie's payout ratio is presently 312.38%.

Hedge Funds Weigh In On AbbVie

Several institutional investors have recently made changes to their positions in the company. Center for Financial Planning Inc. increased its holdings in AbbVie by 15.5% in the 2nd quarter. Center for Financial Planning Inc. now owns 17,025 shares of the company's stock worth $3,160,000 after acquiring an additional 2,283 shares in the last quarter. Continental Investors Services Inc. increased its holdings in AbbVie by 3.9% in the 2nd quarter. Continental Investors Services Inc. now owns 2,327 shares of the company's stock worth $432,000 after acquiring an additional 88 shares in the last quarter. Balentine LLC grew its holdings in shares of AbbVie by 7.5% during the second quarter. Balentine LLC now owns 5,383 shares of the company's stock worth $999,000 after buying an additional 374 shares in the last quarter. Syverson Strege & Co grew its holdings in shares of AbbVie by 30.8% during the second quarter. Syverson Strege & Co now owns 6,006 shares of the company's stock worth $1,115,000 after buying an additional 1,414 shares in the last quarter. Finally, Saxony Capital Management LLC grew its holdings in shares of AbbVie by 10.1% during the second quarter. Saxony Capital Management LLC now owns 2,467 shares of the company's stock worth $458,000 after buying an additional 226 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.